Have you ever bought a stock this bad?

VC hates this right now [DWR Logo]( June 19th 2024 Hi Reader This is ugly. But for investors who went on the wildly-lucrative ride last time, it’s part process Let me take you back to 2012. The healthcare industry was going through major regulatory changes. Future growth prospects were largely unknown with new legislation getting applied throughout the industry. The apprehension hit biotech hard. There were too many variables to know how valuable drug candidates might be in the future. The Nasdaq Biotech Index was lagging far behind the rest of the market. Yes, the Index was up 67% from the 2008 credit crisis low, but it was far behind most other sectors. The world’s top venture capital backed off big time. Life Science VC outlays came in at just $9 billion that year (remember this number). That would all change in the years that followed. Biotech had started a mega-bull market. The Nasdaq Biotech Index climbed 235% by 2015 and went on to rise 359% by the end of 2019. The VC money followed the recovery too. VC life science funding surged from $9 billion in 2012 to more than $27 billion in 2019. Then the pandemic blew the doors off everything with a wild speculative bubble. But that’s over now and the hangover is setting. It’s a bad one too. VC has collapsed for life science projects. This chart shows the rise and fall: [chart] Right now VC life science funding is on pace to go back to levels not seen in years. If history rhymes, there could be another big move for biotech ahead. [Click here to see more big catalysts for biotech.]( [Read More Button]( Dynamic Wealth Research 2010 West Avenue K #623 Lancaster, California 93536 We are sending this message to {EMAIL}. [UNSUBSCRIBE]( | [PRIVACY POLICY](